Cornell has secured a 10-year, $10 million grant renewal to continue work aimed at spurring economic impact and job growth through applied research, development and commercialization of breakthrough technologies.
Scientists fear that the restrictions on Covid mRNA vaccines may impede progress in mRNA cancer research, potentially stalling advancements in treating aggressive cancers such as pancreatic cancer.
"We're able to transform a prolific environmental and societal waste into such a globally important medication in a way that's completely impossible, using chemistry alone or using biology alone," says study coauthor Stephen Wallace, a chemical biotechnologist at the University of Edinburgh in Scotland.
While big names get the spotlight, smaller healthcare stocks often hold the most explosive upside, with potential for significant gains in the coming years.
If there are fewer medical diagnostics there will be fewer medical devices and treatments. Real innovation is a function of risk and reward in a mathematical sense.
Typically, people think about robots as devices that you build with plastic and metal and the wires and software. But because fruit flies are so well understood, they can be treated as living robots.
We are impressed with the team's passion and the early commercial validation of its technology. Alongside HBG Ventures, CHECK24 Impact, and Rockstart, we are excited to support SenseUP's continued growth.
The mosquitoes released in Djibouti are a vital tool in combating malaria, but their effectiveness needs to be complemented by existing prevention methods like nets and vaccines.
Immunologist Jacob Glanville identified a unique opportunity to study the blood of Tim Friede, who gained immunity to snake venom after 18 years of exposure.
Basic research conducted by America's universities is pivotal in fostering an entrepreneurial culture, evidenced by collaborations between academia and notable venture capitalists in technology and medicine.
Sanofi and Alnylam's fitusiran (Qfitlia) is a groundbreaking treatment approved by the FDA for routine prophylaxis in patients with hemophilia A or B, distinguishing itself with a dosing schedule of once every two months.